CELLINK announces extension of collaboration with AstraZeneca to use CELLINKs’ 3D-bioprinting and associated technology for drug discovery

CELLINK scientists will continue to work side-by-side in AstraZeneca labs, aiming to speed discovery of new therapies

CELLINK, focused on the commercialization of innovative technologies for bioprinting and associated technologies for preparation and analysis of 3D-bioprinted tissues, announced today that the company has renewed its agreement to collaborate with the global biopharmaceutical company AstraZeneca for an additional 12 months. CELLINK will provide bioprinters and bioinks to accelerate the exploration of new disease targets in AstraZeneca’s main therapeutic areas, including oncology, respiratory, and cardiovascular, renal and metabolic diseases.

The renewal will leverage CELLINK’s growing portfolio of products which are designed to create a seamless workflow from pre-bioprinting preparation of cells through to post-bioprinting analysis. CELLINK will continue to provide a small team of experts to work side-by-side with AstraZeneca scientists at their Gaithersburg, US, R&D strategic center. AstraZeneca will provide expertise in pharmaceutical development to help CELLINK further refine its product offerings to the needs of the industry.

For further information, please contact:

Erik Gatenholm, CEO                                                                 Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00                                            Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566                                                   Phone (US): +1 (857) 332 2138

E-mail: eg@cellink.com                                                                E-mail: gd@cellink.com

About CELLINK

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.

Latest press releases
November 14, 2019Annual Report 2018/2019